These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1689893)

  • 1. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation.
    Van Thiel DH; Iqbal M; Jain A; Fung J; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):37-40. PubMed ID: 1689893
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathologic observations in human allograft recipients treated with FK 506.
    Demetris AJ; Fung JJ; Todo S; Banner B; Zerbe T; Sysyn G; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):25-34. PubMed ID: 1689891
    [No Abstract]   [Full Text] [Related]  

  • 3. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.
    Fung JJ; Todo S; Jain A; McCauley J; Alessiani M; Scotti C; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):6-12. PubMed ID: 1689901
    [No Abstract]   [Full Text] [Related]  

  • 4. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent.
    Staschak S; Wagner S; Block G; Van Thiel DH; Jain A; Fung J; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):47-9. PubMed ID: 1689896
    [No Abstract]   [Full Text] [Related]  

  • 5. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults.
    Todo S; Fung JJ; Tzakis A; Demetris AJ; Jain A; Alessiani M; Takaya S; Day R; Gordon R; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1397-402. PubMed ID: 1703340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population.
    Nalesnik MA; Demetris AJ; Fung JJ; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1108-10. PubMed ID: 1703335
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.
    Fung JJ; Todo S; Tzakis A; Demetris A; Jain A; Abu-Elmaged K; Alessiani M; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):14-21. PubMed ID: 1703682
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of FK 506 on renal function after liver transplantation.
    McCauley J; Fung J; Jain A; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):17-20. PubMed ID: 1689887
    [No Abstract]   [Full Text] [Related]  

  • 9. The question of FK 506 nephrotoxicity after liver transplantation.
    McCauley J; Takaya S; Fung J; Tzakis A; Abu-Elmagd K; Jain A; Todo S; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1444-7. PubMed ID: 1703344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The side effects of FK 506 in humans.
    Shapiro R; Fung JJ; Jain AB; Parks P; Todo S; Starzl TE
    Transplant Proc; 1990 Feb; 22(1):35-6. PubMed ID: 1689892
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts.
    Lautenschlager I; Höckerstedt K; Mäkisalo H; Orko R; Taskinen E
    Transplant Proc; 1991 Aug; 23(4):2233-5. PubMed ID: 1714650
    [No Abstract]   [Full Text] [Related]  

  • 12. Lymphoproliferative disorders after FK 506.
    Kitahara S; Makuuchi M; Kawasaki S; Ishizone S; Matsunami H; Kamada N; Kawarazaki H; Iwanaka T
    Lancet; 1991 May; 337(8751):1234. PubMed ID: 1708846
    [No Abstract]   [Full Text] [Related]  

  • 13. Glucose and lipid metabolism in liver transplant patients under long-term tacrolimus (FK 506) monotherapy.
    Loss M; Winkler M; Schneider A; Oldhafer K; Manns MP; Pichlmayr R
    Transplant Proc; 1996 Apr; 28(2):1006-7. PubMed ID: 8623210
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.
    Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P
    J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The determination of metabolite M17 and its meaning for immunosuppressive cyclosporin therapy.
    Khoschsorur G; Auer T; Lanzer G; Petritsch P; Holzer H; Tscheliessnigg KH
    Angiology; 1998 Apr; 49(4):307-14. PubMed ID: 9555934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
    Jacob DA; Neumann UP; Bahra M; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1691-2. PubMed ID: 15919432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates.
    Monden M; Gotoh M; Kanai T; Valdivia LA; Umeshita K; Endoh W; Nakano Y; Kawai M; Ohzato H; Ukei T
    Transplant Proc; 1990 Feb; 22(1):66-71. PubMed ID: 1689904
    [No Abstract]   [Full Text] [Related]  

  • 18. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children.
    Tumgor G; Arikan C; Kilic M; Aydogdu S
    Pediatr Transplant; 2006 Sep; 10(6):665-8. PubMed ID: 16911488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.
    McCauley J; Bronsther O; Fung J; Todo S; Starzl TE
    Lancet; 1989 Dec 23-30; 2(8678-8679):1516. PubMed ID: 2481200
    [No Abstract]   [Full Text] [Related]  

  • 20. [Immunosuppression and the problems in partial liver transplantation].
    Kawasaki M; Hashikura Y; Matsunami H; Makunouchi M
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):683. PubMed ID: 8963785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.